Trials / Recruiting
RecruitingNCT05372354
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
An Exploratory Phase 1b/2a Multicenter, Open-Label, Novel-Novel Combination Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of CC-92480 (BMS-986348) in Novel Therapeutic Combinations in Participants With Relapsed or Refractory Multiple Myeloma
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 260 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety, tolerability and preliminary effectiveness of CC-92480 (BMS-986348) in novel therapeutic combinations for the treatment of Relapsed or Refractory Multiple Myeloma (RRMM).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CC-92480 | Specified dose on specified days |
| DRUG | Tazemetostat | Specified dose on specified days |
| DRUG | BMS-986158 | Specified dose on specified days |
| DRUG | Trametinib | Specified dose on specified days |
| DRUG | Dexamethasone | Specified dose on specified days |
Timeline
- Start date
- 2022-10-18
- Primary completion
- 2026-10-12
- Completion
- 2026-10-12
- First posted
- 2022-05-12
- Last updated
- 2025-09-05
Locations
17 sites across 5 countries: United States, Canada, Norway, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05372354. Inclusion in this directory is not an endorsement.